405 related articles for article (PubMed ID: 27467716)
1. Comparison of 18F-FES, 18F-FDG, and 18F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer.
He S; Wang M; Yang Z; Zhang J; Zhang Y; Luo J; Zhang Y
PLoS One; 2016; 11(7):e0159916. PubMed ID: 27467716
[TBL] [Abstract][Full Text] [Related]
2. Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
Kurland BF; Peterson LM; Lee JH; Schubert EK; Currin ER; Link JM; Krohn KA; Mankoff DA; Linden HM
Clin Cancer Res; 2017 Jan; 23(2):407-415. PubMed ID: 27342400
[TBL] [Abstract][Full Text] [Related]
3. 18F-fluoromisonidazole PET/CT: a potential tool for predicting primary endocrine therapy resistance in breast cancer.
Cheng J; Lei L; Xu J; Sun Y; Zhang Y; Wang X; Pan L; Shao Z; Zhang Y; Liu G
J Nucl Med; 2013 Mar; 54(3):333-40. PubMed ID: 23401605
[TBL] [Abstract][Full Text] [Related]
4. [18F]-fluoroestradiol quantitative PET imaging to differentiate ER+ and ERα-knockdown breast tumors in mice.
Paquette M; Ouellet R; Archambault M; Croteau É; Lecomte R; Bénard F
Nucl Med Biol; 2012 Jan; 39(1):57-64. PubMed ID: 22079037
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
[TBL] [Abstract][Full Text] [Related]
6. Optimization of Early Response Monitoring and Prediction of Cancer Antiangiogenesis Therapy via Noninvasive PET Molecular Imaging Strategies of Multifactorial Bioparameters.
Bao X; Wang MW; Luo JM; Wang SY; Zhang YP; Zhang YJ
Theranostics; 2016; 6(12):2084-2098. PubMed ID: 27698942
[No Abstract] [Full Text] [Related]
7. The feasibility of
Liu S; Gu B; Zhang J; Zhang Y; Xu X; Yuan H; Zhang Y; Yang Z
Ann Nucl Med; 2018 May; 32(4):272-280. PubMed ID: 29478216
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal Molecular Imaging of Progesterone Receptor Reveals Early Differential Response to Endocrine Therapy in Breast Cancer with an Activating
Kumar M; Salem K; Jeffery JJ; Yan Y; Mahajan AM; Fowler AM
J Nucl Med; 2021 Apr; 62(4):500-506. PubMed ID: 32859700
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.
Heidari P; Deng F; Esfahani SA; Leece AK; Shoup TM; Vasdev N; Mahmood U
Clin Cancer Res; 2015 Mar; 21(6):1340-7. PubMed ID: 25609068
[TBL] [Abstract][Full Text] [Related]
10. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract][Full Text] [Related]
11. Small-animal PET of steroid hormone receptors predicts tumor response to endocrine therapy using a preclinical model of breast cancer.
Fowler AM; Chan SR; Sharp TL; Fettig NM; Zhou D; Dence CS; Carlson KE; Jeyakumar M; Katzenellenbogen JA; Schreiber RD; Welch MJ
J Nucl Med; 2012 Jul; 53(7):1119-26. PubMed ID: 22669982
[TBL] [Abstract][Full Text] [Related]
12. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using
Jager A; de Vries EGE; der Houven van Oordt CWM; Neven P; Venema CM; Glaudemans AWJM; Wang Y; Bagley RG; Conlan MG; Aftimos P
Breast Cancer Res; 2020 Sep; 22(1):97. PubMed ID: 32912274
[TBL] [Abstract][Full Text] [Related]
13. Monitoring the Early Response of Fulvestrant Plus Tanshinone IIA Combination Therapy to Estrogen Receptor-Positive Breast Cancer by Longitudinal
He S; Wang M; Zhang Y; Luo J; Zhang Y
Contrast Media Mol Imaging; 2019; 2019():2374565. PubMed ID: 31281233
[TBL] [Abstract][Full Text] [Related]
14. Clinical production, stability studies and PET imaging with 16-alpha-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients.
Kumar P; Mercer J; Doerkson C; Tonkin K; McEwan AJ
J Pharm Pharm Sci; 2007; 10(2):256s-265s. PubMed ID: 17718929
[TBL] [Abstract][Full Text] [Related]
15.
Liu C; Gong C; Liu S; Zhang Y; Zhang Y; Xu X; Yuan H; Wang B; Yang Z
Oncologist; 2019 Dec; 24(12):e1277-e1285. PubMed ID: 31337657
[TBL] [Abstract][Full Text] [Related]
16. The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients.
Sun Y; Yang Z; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
PLoS One; 2015; 10(1):e0116341. PubMed ID: 25617853
[TBL] [Abstract][Full Text] [Related]
17. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer.
Linden HM; Stekhova SA; Link JM; Gralow JR; Livingston RB; Ellis GK; Petra PH; Peterson LM; Schubert EK; Dunnwald LK; Krohn KA; Mankoff DA
J Clin Oncol; 2006 Jun; 24(18):2793-9. PubMed ID: 16682724
[TBL] [Abstract][Full Text] [Related]
18. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.
Dehdashti F; Mortimer JE; Trinkaus K; Naughton MJ; Ellis M; Katzenellenbogen JA; Welch MJ; Siegel BA
Breast Cancer Res Treat; 2009 Feb; 113(3):509-17. PubMed ID: 18327670
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.
Dehdashti F; Flanagan FL; Mortimer JE; Katzenellenbogen JA; Welch MJ; Siegel BA
Eur J Nucl Med; 1999 Jan; 26(1):51-6. PubMed ID: 9933662
[TBL] [Abstract][Full Text] [Related]
20. 18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis.
Evangelista L; Guarneri V; Conte PF
Curr Radiopharm; 2016; 9(3):244-257. PubMed ID: 27774910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]